OrderlyMeds: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of OrderlyMeds' website, https://orderlymeds.com, FDA Establishment Identifier (FEI) 3044027176, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “1. The compounded semaglutide and tirzepatide products displayed on your website feature OrderlyMeds' logo on the pictured label, suggesting OrderlyMeds is the compounder of those drugs when in fact it is not.”

2. 2

   “2. Your website claims that the compounded drug products it offers are sourced from an “FDA-licensed pharmacy.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&C Act does not establish an “FDA-approved” or “FDA-licensed” designation for pharmacies or outsourcing facilities.”

3. 3

   “Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

orderlymeds.com returned a live storefront on 2026-08-09, titled "Online Compounded GLP-1 Medications by OrderlyMeds", with published prices, a cart and the Decatur, Georgia address the letter gives.

Two small things here are worth more than the letter's length suggests. First, the label finding needed no words — a logo on the pictured vial was enough for FDA to say the site implies OrderlyMeds compounds a product it does not compound. If you have been screening sellers by reading their copy, that is a gap in the method: the product photo makes the claim before any sentence does. Second, "FDA-licensed pharmacy" is the reassurance you are most likely to accept at face value when a price looks low, and FDA states here that the designation does not exist. Neither finding says anything about whether this medicine is good or this price is fair. What they take away is the shortcut — you cannot read "our own label, from an FDA-licensed pharmacy" as two independent guarantees, because one describes a print job and the other describes a status no regulator confers.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence OrderlyMeds failed to respond.